Astex Pharmaceuticals

Astex logo

Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. As part of Japan's leading pharmaceutical company, Otsuka Pharmaceutical Co. Ltd., Astex operates from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA.

We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Although our discovery platform has been successfully applied to therapeutic targets addressing a variety of disease areas, our primary clinical area of focus is currently cancer. In addition, we are expanding our capabilities and building expertise in the area of fragment-based drug discovery for diseases of the CNS which we plan to develop through collaboration with our parent company, Otsuka, or with other pharmaceutical company partners.

Contact Astex Pharmaceuticals via their website

News Archives

14/04/2021   Astex Pharmaceuticals reports NCCN Projects to Study Oral Decitabine and Cedazuridine...more

28/10/2020   Astex Pharmaceuticals CRADA with U.S. National Cancer Institute...more
14/10/2020   Astex and Otsuka announce phase 3 ASTRAL trial studies results...more
08/09/2020   Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration...more
31/08/2020   Astex Pharmaceuticals Announces ASTX660 Granted FDA Orphan Drug Designation...more
07/07/2020   Astex Pharmaceuticals announces FDA and Health Canada approval of INQOVI®...more
11/02/2020   Astex Pharmaceuticals announces FDA acceptance for NDA review of ASTX727...more

09/12/2019   Astex Pharmaceuticals presents topline phase 3 study data...more
03/09/2019   Astex Pharmaceuticals announces ASTX727 granted FDA orphan drug designation...more
07/06/2019   Taiho Oncology to Commercialize Astex Pharmaceuticals’ Drug Candidates ...more
07/06/2019   British Company Behind Groundbreaking Breast Cancer Treatment ...more
06/06/2019   Astex Pharmaceuticals and Otsuka announce ASTX727 study results ...more
12/04/2019   BALVERSA™ discovered by Astex and Janssen receives FDA approval...more

09/05/2018   Astex's Harren Jhoti Made Fellow of the Royal Society...more
15/03/2018   Astex announces US FDA Breakthrough Therapy Designation for erdafitinib...more
26/01/2018   Astex Pharmaceuticals' Harren Jhoti Receives Lifetime Achievement Award from BIA...more
19/01/2018   Astex Pharmaceuticals: Otsuka Signs Women's Empowerment Statement...more

24/08/2017   Astex Pharmaceuticals Celebrates as Cancer Drug Receives European Marketing Approval...more
13/03/2017   Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval...more

21/11/2016   Astex Joins the Dementia Discovery Fund as a Strategic Investor...more
14/10/2016   Astex scientist, Alison Woolford, Wins Capps Green Zomaya Award...more
19/04/2016   Astex Pharmaceuticals Enters Clinical Trial Collaboration...more

06/10/2015   Astex Pharmaceuticals Announces Orphan Drug Designation for Guadecitabine...more
01/09/2015   Open Innovation Article Features Astex Pharmaceuticals President and CEO ...more
18/08/2015   Astex Pharmaceuticals Announces Key Clinical Data Published in Lancet Oncology...more

16/06/2014   Astex Pharmaceuticals Presents Final Results of Phase 2 SGI-110 Study...more
04/03/2014   Astex Earns Milestone Payment on Initiation of Phase 3 Study...more

11/10/2013   Otsuka Pharmaceutical Completes Acquisition of Astex Pharmaceuticals...more
05/09/2013   Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals for $8.50 Per Share in Cash...more
28/08/2013   Astex Pharmaceuticals Announces Topline Results Phase 2 Study...more
22/07/2013   Astex Pharmaceuticals Announces HSP90 Inhibitor AT13387 First Data...more
08/07/2013   Astex Pharmaceuticals Announces IND Candidate: ASTX727...more
20/06/2013   Astex Pharmaceuticals will present updated SGI-110 data at European Cancer Congress...more
14/06/2013   Astex Pharmaceuticals Announces Presentation of Updated SGI-110-01 Study Results...more
10/04/2013   Astex Pharmaceuticals Provides SGI-110 Update...more
16/01/2013   Astex Pharmaceuticals collaborators launch clinical trial to treat several cancer types...more

29/10/2012   Astex Pharmaceuticals Signs Strategic Drug Discovery Alliance...more
09/10/2012   Astex Pharmaceuticals Earns $5 Million for First Commercial Sale of DACOGEN®...more
04/10/2012   Astex Pharmaceuticals President Harren Jhoti elected to UK BioIndustry Association Board...more
02/10/2012   Astex Pharmaceuticals Announces Initiation of SGI-110 Phase 2 Trial...more
28/09/2012   DACOGEN® Approved in the European Union for the Treatment of Acute Myeloid Leukemia...more
10/09/2012   Astex Pharmaceuticals Announces Clinical Trial in Prostate Cancer Patients...more
07/09/2012   Astex and ICR in Epigenetic Discvery Collaboration...more
20/08/2012   Astex Pharmaceuticals Award for New Technologies in Drug Discovery...more
22/06/2012   Astex Pharmaceuticals Announces Phase 2 Expansion of SGI-110 Clinical Trial...more
13/06/2012   Astex Pharmaceuticals Earns $5.4 Million Milestone...more
03/01/2012   Astex Pharmaceuticals to Present at Biotech Showcase on January 9th...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code